Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin ludefen - Gan & Lee Pharmaceuticals

Next Previous
Drug Profile

Insulin ludefen - Gan & Lee Pharmaceuticals

Alternative Names: GZR-4; Insulin Ludefen - Gan & Lee Pharmaceuticals; Long acting insulin analog - Gan & Lee Pharmaceuticals

Latest Information Update: 10 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gan&Lee Pharmaceuticals
  • Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase I Diabetes mellitus

Most Recent Events

  • 07 Aug 2026 Gan&Lee Pharmaceuticals terminates a phase I trial in Type 2 diabetes mellitus in Germany (SC) due to sponsors decesion (NCT07146347) (CTIS2025-522662-67-00) (CTIS2024-519646-73-00)
  • 17 Jul 2026 Phase-I clinical trials in Diabetes mellitus in North America, Europe (SC) prior to July 2026 (Gan & Lee Pharmaceuticals pipeline, July 2026)
  • 01 Jul 2026 Gan & Lee Pharmaceuticals plans a phase I trial in Healthy adult volunteers in China (SC, Injection) in July 2026 (NCT07670897)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top